Attana participates at the Drug Discovery Innovation Programme, DDIP 2019, Barcelona November 28-29, 2019
The DDIP-conference focus on new technologies for improved drug development. At the conference leading professionals within industry and academy will participate. Attana will give a presentation at the scientific session and have an exhibition booth.
Attana’s CEO Teodor Aastrup will give the presentation “In vivo Predictions by Attana”. Focus will be on how Attana’s 3rd generation biosensor has increased the efficiency in drug development.
To learn more about the conference and the participants please read here.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
Tags:
